Skip to main content
SpringerLink
Log in

Anti-Inflammatory Therapeutic Approaches

  • Chapter
  • First Online:
Inflammation and Atherosclerosis

Abstract

Accelerated atherosclerosis and increased cardiovascular (CV) risk have become 3 major factors of mortality in inflammatory diseases. Most data have become avail- 4 able in rheumatoid arthritis (RA), however, vasculopathies have also been 5 associated with spondylarthropathies (SpA), systemic lupus erythematosus (SLE), 6 antiphospholipid syndrome (APS), systemic sclerosis (SSc, scleroderma) and sys- 7 temic vasculitides [1–19].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T et al (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9(12):849–852

    Article  PubMed  Google Scholar 

  2. Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2(6):320–329

    Article  PubMed  CAS  Google Scholar 

  3. Szekanecz Z, Kerekes G, Der H, Sandor Z, Szabo Z, Vegvari A et al (2007) Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 1108:349–358

    Article  PubMed  CAS  Google Scholar 

  4. Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A et al (2005) Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 1051:281–290

    Article  PubMed  Google Scholar 

  5. Kaplan MJ (2006) Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 18(3):289–297

    Article  PubMed  CAS  Google Scholar 

  6. Nurmohamed MT (2009) Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 8(8):663–667

    Article  PubMed  Google Scholar 

  7. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al (2009) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325

    Article  PubMed  Google Scholar 

  8. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347

    Article  PubMed  Google Scholar 

  9. Soltesz P, Der H, Kerekes G, Szodoray P, Szucs G, Danko K et al (2009) A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 28(6):655–662

    Article  PubMed  Google Scholar 

  10. Szucs G, Timar O, Szekanecz Z, Der H, Kerekes G, Szamosi S et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis – relevance for prevention of vascular complications. Rheumatology (Oxford) 46(5):759–762

    Article  CAS  Google Scholar 

  11. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1(6):338–347

    Article  PubMed  CAS  Google Scholar 

  12. Hahn BH, McMahon M (2008) Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies. Lupus 17(5):368–370

    Article  PubMed  CAS  Google Scholar 

  13. Salmon JE, Roman MJ (2001) Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 13(5):341–344

    Article  PubMed  CAS  Google Scholar 

  14. Szamosi S, Csiki Z, Szomjak E, Szolnoki E, Szoke G, Szekanecz Z et al (2009) Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: risk factors for accelerated macrovascular damage? Clin Rev Allergy Immunol 36(2–3):145–149

    Article  PubMed  Google Scholar 

  15. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y (2007) Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 6(6):379–386

    Article  PubMed  CAS  Google Scholar 

  16. Shoenfeld Y, Harats D, George J (1998) Atherosclerosis and the antiphospholipid syndrome: a link unravelled? Lupus 7(Suppl 2):S140–S143

    Article  PubMed  Google Scholar 

  17. Bacon PA (2005) Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol 17(1):49–55

    Article  PubMed  CAS  Google Scholar 

  18. Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L et al (2009) Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 8(4):281–286

    Article  PubMed  Google Scholar 

  19. Turiel M, Sitia S, Atzeni F, Tomasoni L, Gianturco L, Giuffrida M et al (2010) The heart in rheumatoid arthritis. Autoimmun Rev 9(6):414–418

    Article  PubMed  CAS  Google Scholar 

  20. Szekanecz Z, Koch AE (2008) Vascular involvement in rheumatic diseases: ‘vascular rheumatology’. Arthritis Res Ther 10(5):224

    Article  PubMed  CAS  Google Scholar 

  21. Ross R (1999) Atherosclerosis – an inflammatory disease. N Engl J Med 340(2):115–126

    Article  PubMed  CAS  Google Scholar 

  22. Ohsuzu F (2004) The roles of cytokines, inflammation and immunity in vascular diseases. J Atheroscler Thromb 11(6):313–321

    Article  PubMed  CAS  Google Scholar 

  23. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L et al (2008) Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 35(3):398–406

    PubMed  CAS  Google Scholar 

  24. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A et al (2006) Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 24(4):373–379

    PubMed  CAS  Google Scholar 

  25. Bruce IN (2005) Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 19(5):823–838

    Article  PubMed  CAS  Google Scholar 

  26. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62(11):1071–1077

    Article  PubMed  CAS  Google Scholar 

  27. Baulmann J, Schillings U, Rickert S, Uen S, Dusing R, Illyes M et al (2008) A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J Hypertens 26(3):523–528

    Article  PubMed  CAS  Google Scholar 

  28. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39(2):257–265

    Article  PubMed  Google Scholar 

  29. Kanters SD, Algra A, van Leeuwen MS, Banga JD (1997) Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 28(3):665–671

    Article  PubMed  CAS  Google Scholar 

  30. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A et al (2010) From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9(12):830–834

    Article  PubMed  CAS  Google Scholar 

  31. Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM et al (2007) Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50(9):852–858

    Article  PubMed  CAS  Google Scholar 

  32. Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S et al (2010) The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 9(12):835–839

    Article  PubMed  CAS  Google Scholar 

  33. Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, et al (2010) Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early Rheumatoid Arthritis. Cardiovasc Ther 28(5):e53–64

    Google Scholar 

  34. Suissa S, Bernatsky S, Hudson M (2006) Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 55(4):531–536

    Article  PubMed  CAS  Google Scholar 

  35. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8(5):R151

    Article  PubMed  CAS  Google Scholar 

  36. Szekanecz Z, Kerekes G, Soltesz P (2009) Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 5(12):677–684

    Article  PubMed  CAS  Google Scholar 

  37. Klareskog L, Hamsten A (2004) Statins in rheumatoid arthritis–two birds with one stone? Lancet 363(9426):2011–2012

    Article  PubMed  Google Scholar 

  38. Van Doornum S, Jennings GL, Wicks IP (2006) Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 184(6):287–290

    PubMed  Google Scholar 

  39. Singh G, Wu O, Langhorne P, Madhok R (2006) Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 8(5):R153

    Article  PubMed  CAS  Google Scholar 

  40. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332(7553):1302–1308

    Article  PubMed  CAS  Google Scholar 

  41. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296(13):1633–1644

    Article  PubMed  CAS  Google Scholar 

  42. Nurmohamed MT, van Halm VP, Dijkmans BA (2002) Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 62(11):1599–1609

    Article  PubMed  CAS  Google Scholar 

  43. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL (2007) Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66(10):1296–1304

    Article  PubMed  CAS  Google Scholar 

  44. Abramson SB, Greenberg JD (2008) Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction? Nat Clin Pract Rheumatol 4(4):182–183

    Article  PubMed  CAS  Google Scholar 

  45. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817

    Article  PubMed  CAS  Google Scholar 

  46. MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357):573–574

    Article  PubMed  CAS  Google Scholar 

  47. Katz JD, Shah T (2009) Persistent pain in the older adult: what should we do now in light of the 2009 American geriatrics society clinical practice guideline? Pol Arch Med Wewn 119(12):795–800

    PubMed  Google Scholar 

  48. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64(5):669–681

    Article  PubMed  CAS  Google Scholar 

  49. Bulkley BH, Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58(2):243–264

    Article  PubMed  CAS  Google Scholar 

  50. Maxwell SR, Moots RJ, Kendall MJ (1994) Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 70(830):863–870

    Article  PubMed  CAS  Google Scholar 

  51. Petri M, Lakatta C, Magder L, Goldman D (1994) Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96(3):254–259

    Article  PubMed  CAS  Google Scholar 

  52. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA et al (2008) Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 59(2):169–175

    Article  PubMed  CAS  Google Scholar 

  53. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loet X, Pham T (2010) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 78(1):23–30

    Google Scholar 

  54. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27(9):2142–2145

    PubMed  CAS  Google Scholar 

  55. Sachet JC, Borba EF, Bonfa E, Vinagre CG, Silva VM, Maranhao RC (2007) Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16(4):273–278

    Article  PubMed  CAS  Google Scholar 

  56. Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28(4):780–785

    PubMed  CAS  Google Scholar 

  57. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87(3):518–522

    PubMed  CAS  Google Scholar 

  58. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28

    Article  PubMed  CAS  Google Scholar 

  59. Bruce IN (2005) 'Not only…but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44(12):1492–1502

    Article  CAS  Google Scholar 

  60. Feeley BT, Park AK, Hoyt EG, Robbins RC (1999) Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants. J Heart Lung Transplant 18(11):1088–1095

    Article  PubMed  CAS  Google Scholar 

  61. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC et al (1996) The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156(5):1937–1941

    PubMed  CAS  Google Scholar 

  62. Baskan BM, Sivas F, Aktekin LA, Dogan YP, Ozoran K, Bodur H (2009) Serum homocysteine level in patients with ankylosing spondylitis. Rheumatol Int 29(12):1435–1439

    Article  PubMed  CAS  Google Scholar 

  63. Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873

    Article  PubMed  Google Scholar 

  64. Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H et al (2008) Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 58(12):3675–3683

    Article  PubMed  CAS  Google Scholar 

  65. Feng H, Li XY, Zheng JR, Gao JW, Xu LF, Tang MY (2005) Inhibition of the nuclear factor-kappaB signaling pathway by leflunomide or triptolide also inhibits the anthralin-induced inflammatory response but does not affect keratinocyte growth inhibition. Biol Pharm Bull 28(9):1597–1602

    Article  PubMed  CAS  Google Scholar 

  66. Minoretti P, Bruno A, Di Vito C, Emanuele E (2007) Leflunomide as an antiatherogenic drug. Med Hypotheses 68(5):1175–1176

    Article  PubMed  CAS  Google Scholar 

  67. Grisar J, Aringer M, Koller MD, Stummvoll GH, Eselbock D, Zwolfer B et al (2004) Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 63(12):1632–1637

    Article  PubMed  CAS  Google Scholar 

  68. Deuse T, Erben RG, Ikeno F, Behnisch B, Boeger R, Connolly AJ et al (2008) Introducing the first polymer-free leflunomide eluting stent. Atherosclerosis 200(1):126–134

    Article  PubMed  CAS  Google Scholar 

  69. Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A et al (2009) Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 1173:814–821

    Article  PubMed  Google Scholar 

  70. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106(17):2184–2187

    Article  PubMed  Google Scholar 

  71. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P et al (2008) TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27(7):833–839

    Article  PubMed  Google Scholar 

  72. Bilsborough W, Keen H, Taylor A, O’Driscoll GJ, Arnolda L, Green DJ (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26(12):1125–1131

    Article  PubMed  CAS  Google Scholar 

  73. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA (2004) Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 51(3):447–450

    Article  PubMed  CAS  Google Scholar 

  74. Mazzoccoli G, Notarsanto I, de Pinto GD, Pia Dagostino M, De Cata A, D’Alessandro G, et al (2010) Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 5(6):495–500

    Google Scholar 

  75. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA (2006) Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 24(3):309–312

    PubMed  CAS  Google Scholar 

  76. Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D et al (2009) Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 38(1):6–10

    Article  PubMed  CAS  Google Scholar 

  77. Capria A, De Nardo D, Baffetti FR, Barbini U, Violo A, Tondo T et al (2010) Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 23(1):255–262

    PubMed  CAS  Google Scholar 

  78. Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M et al (2007) Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 46(7):1111–1115

    Article  CAS  Google Scholar 

  79. Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G et al (2009) Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 68(8):1277–1284

    Article  PubMed  CAS  Google Scholar 

  80. Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW et al (2006) Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 114(11):1185–1192

    Article  PubMed  CAS  Google Scholar 

  81. Cypiene A, Laucevicius A, Venalis A, Ryliskyte L, Dadoniene J, Petrulioniene Z et al (2007) Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc 50:119–122

    PubMed  CAS  Google Scholar 

  82. Van Doornum S, McColl G, Wicks IP (2005) Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 44(11):1428–1432

    Article  Google Scholar 

  83. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33(5):921–923

    PubMed  CAS  Google Scholar 

  84. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R et al (2005) Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32(2):252–255

    PubMed  CAS  Google Scholar 

  85. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26(9):1495–1498

    Article  PubMed  Google Scholar 

  86. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M (2006) Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:414–419

    Article  PubMed  CAS  Google Scholar 

  87. Soubrier M, Jouanel P, Mathieu S, Poujol D, Claus D, Dubost JJ et al (2008) Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75(1):22–24

    Article  PubMed  CAS  Google Scholar 

  88. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M et al (2007) Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 66(11):1503–1507

    Article  PubMed  CAS  Google Scholar 

  89. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL et al (2005) Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64(2):303–305

    Article  PubMed  CAS  Google Scholar 

  90. Garces SP, Parreira Santos MJ, Vinagre FM, Roque RM, da Silva JA (2008) Anti-tumour necrosis factor agents and lipid profile: a class effect? Ann Rheum Dis 67(6):895–896

    Article  PubMed  CAS  Google Scholar 

  91. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17(5):385–390

    Article  PubMed  CAS  Google Scholar 

  92. Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y (2008) Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 55(1):213–216

    Article  PubMed  CAS  Google Scholar 

  93. Lewicki M, Kotyla P, Kucharz E (2008) Etanercept increases adiponectin level in woman with rheumatoid arthritis. Clin Rheumatol 27(10):1337–1338

    Article  PubMed  Google Scholar 

  94. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN (2009) Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol 23(5):595–600

    Article  PubMed  CAS  Google Scholar 

  95. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM et al (2008) Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26(2):311–316

    PubMed  CAS  Google Scholar 

  96. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR et al (2009) Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 27(2):222–228

    PubMed  CAS  Google Scholar 

  97. Bajnok L, Csongradi E, Seres I, Varga Z, Jeges S, Peti A et al (2008) Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis 197(1):363–367

    Article  PubMed  CAS  Google Scholar 

  98. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I et al (2008) Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58(7):2105–2112

    Article  PubMed  CAS  Google Scholar 

  99. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA (2007) Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194(3):539–550

    Article  PubMed  CAS  Google Scholar 

  100. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193(1):153–159

    Article  PubMed  CAS  Google Scholar 

  101. Ursini F, Naty S, Grembiale RD (2010) Infliximab and insulin resistance. Autoimmun Rev 9(8):536–539

    Article  PubMed  CAS  Google Scholar 

  102. Seriolo B, Ferrone C, Cutolo M (2008) Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol 35(2):355–357

    PubMed  CAS  Google Scholar 

  103. Huvers FC, Popa C, Netea MG, van den Hoogen FH, Tack CJ (2007) Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 66(4):558–559

    Article  PubMed  CAS  Google Scholar 

  104. da Silva BS, Bonfa E, de Moraes JC, Saad CG, Ribeiro AC, Goncalves CR et al (2010) Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals 38(5):567–569

    Article  PubMed  CAS  Google Scholar 

  105. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE (2010) Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 22(3):299–306

    Article  PubMed  CAS  Google Scholar 

  106. Szekanecz Z, Koch AE (2010) Vasculogenesis in rheumatoid arthritis. Arthritis Res Ther 12(2):110

    Article  PubMed  Google Scholar 

  107. Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D et al (2006) Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 79(25):2364–2369

    Article  PubMed  CAS  Google Scholar 

  108. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Saemann M et al (2007) Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 66(10):1284–1288

    Article  PubMed  CAS  Google Scholar 

  109. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D et al (2005) Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111(2):204–211

    Article  PubMed  Google Scholar 

  110. Karkucak M, Capkin E, Alver A, Akyuz A, Kiris A, Ak E et al (2010) The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Clin Rheumatol 29(3):303–307

    Article  PubMed  Google Scholar 

  111. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32(7):1213–1218

    PubMed  CAS  Google Scholar 

  112. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56(9):2905–2912

    Article  PubMed  CAS  Google Scholar 

  113. Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116(5):305–311

    Article  PubMed  Google Scholar 

  114. Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A et al (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 28(6):705–710

    Article  PubMed  Google Scholar 

  115. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59(12):1821–1824

    Article  PubMed  CAS  Google Scholar 

  116. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54(9):2817–2829

    Article  PubMed  CAS  Google Scholar 

  117. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E et al (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58(10):2968–2980

    Article  PubMed  CAS  Google Scholar 

  118. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, et al (2009) Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 31(4):451–456

    Google Scholar 

  119. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963

    Article  PubMed  Google Scholar 

  120. Ridker PM (2004) High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 148(1 Suppl):S19–S26

    Article  PubMed  CAS  Google Scholar 

  121. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF et al (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 61(11):1571–1579

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary

    Zoltán Szekanecz

  2. Third Department of Medicine, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary

    György Kerekes

  3. Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

    Yehuda Shoenfeld

Authors
  1. Zoltán Szekanecz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. György Kerekes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yehuda Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zoltán Szekanecz .

Editor information

Editors and Affiliations

  1. Medical University Innsbruck, Peter-Mayr-Strasse 4 a, Innsbruck, 6020, Austria

    Georg Wick

  2. Laboratory of Autoimmunity, Division of Experimental Pathophysiology, Biocenter, Innsbruck Medical University, Schöpfstraße 41, Innsbruck, 6020, Austria

    Cecilia Grundtman

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag/Wien

About this chapter

Cite this chapter

Szekanecz, Z., Kerekes, G., Shoenfeld, Y. (2012). Anti-Inflammatory Therapeutic Approaches. In: Wick, G., Grundtman, C. (eds) Inflammation and Atherosclerosis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0338-8_26

Download citation

Publish with us

Policies and ethics

Search

Navigation